Company intelligence / Profile preview

BodyBio

Millville, New Jersey, United Statesbodybio.com ↗

Ownership: Private
Development stage: Commercial

Overview

BodyBio’s products are commercially available dietary supplements focused on supporting cellular health. There are no clinical trial results published; efficacy claims are based on scientific literature and practitioner experience rather than formal drug development studies.[1][2][4]

Therapeutic areas: Metabolic DisordersImmunologyOtherGastroenterologyNeurology
Modalities: Small molecule (e.g., sodium butyrate)Lipid-based supplement (e.g., phospholipids, essential fatty acids)Biologic (bile acids such as TUDCA)Vitamin/mineral supplement
Industry: Food & Nutrition

Drug pipeline

4 assets

BodyBio PC

Commercial

Indications: Cognitive function, Cellular health

3 more assets in the full pipeline.

Request access →

Partnerships

None known

Beyond the preview

Go deeper on BodyBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BodyBio.

Explore the full profile